Central diabetes insipidus (DI), now formally termed arginine vasopressin deficiency (AVP-D) [1], is a rare endocrine disorder characterized by insufficient secretion of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), from the posterior pituitary gland [2]. This hormonal deficiency results in the production of large volumes of dilute urine and excessive thirst, significantly impairing patients’ quality of life. The cornerstone of treatment for central DI is desmopressin (1-deamino-8-d-arginine vasopressin, DDAVP), a synthetic analog of AVP, which effectively manages symptoms by reducing urine output and restoring water balance [2].
